Abstract：Objective To investigate the clinical characteristics of patients with coronavirus disease 2019 (COVID-19) in Bozhou city, Anhui province. Methods We collected clinical data concerning 108 confirmed COVID-19 patients in Bozhou city from January 21 to March 5 in 2020, and then analyzed retrospectively. Results There were 91 symptomatic patients (84.26%, 91/108) and 17 asymptomatic patients (15.74%, 17/ 108) among the 108 confirmed COVID-19 patients. 5 cases were severe and critical patients (4.63%, 5/108). The median ages of the confirmed patients and the asymptomatic patients were 42 and 33 years, respectively. There were fewer patients with underlying diseases (8.33%, 9/108). The lymphocyte count of the asymptomatic patients was not decreased. 63.74% (58/91) of the symptomatic patients and 17.64% (14/17) of the asymptomatic patients showed an increase in high-sensitivity C-reactive protein (hs-CRP). 72.53% (66/91) of the symptomatic patients and 29.41% (5/17) of the asymptomatic patients had a rapid increase in erythrocyte sedimentation rate (ESR). 43.96% (40/91) of the symptomatic patients and 5.88% (1/17) of the asymptomatic patients showed an increase in lactate dehydrogenase (LDH). The main changes of lung CT in the symptomatic patients were double pneumonia (86.81%, 79/91), whereas the main manifestations of lung CT in the asymptomatic patients were single pneumonia (52.94%, 9/17) or non-inflammation (41.18%, 7/17). Interferon α combined with traditional Chinese medicine was the main therapeutic regimen, and all the patients were cured. Conclusions The confirmed COVID-19 patients in Bozhou city were in a mild condition, and there were fewer asymptomatic patients in the early stage of the epidemic. There existed abnormal changes in ESR, hs-CRP and LDH of the symptomatic patients. Imaging abnormalities were also found in lung CT of the asymptomatic patients, and lung CT of some symptomatic patients showed no inflammatory changes.
韩若东, 马景贺, 艾辉, 杜文杰, 钱贝丽, 颜秀侠. 108例新型冠状病毒肺炎患者的临床特征分析[J]. 实用预防医学, 2020, 27(9): 1040-1043.
HAN Ruo-dong, MA Jing-he, AI Hui, DU Wen-jie, QIAN Be-li, YAN Xiu-xia. Clinical characteristics of 108 patients with COVID-19 infection. , 2020, 27(9): 1040-1043.
[1] Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster[J]. Lancet, 2020, 395(10223):514-523. [2] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020,395(10223):497-506. [3] 陈水连, 周银柱, 张恒, 等. 长沙市新型冠状病毒肺炎流行特征分析[J]. 实用预防医学, 2020, 27(5):527-529. [4] 华中科技大学同济医学院附属同济医院救治医疗专家组. 新型冠状病毒感染的肺炎诊疗快速指南(第三版)[J]. 医药导报, 2020, 39(3):305-307. [5] Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study[J]. Lancet, 2020, 395(10225):689-697. [6] Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak[J]. Int J Infect Dis, 2020,92:214-217. [7] 李朝晖, 郭小成, 马智泉, 等. 邵阳市94例新型冠状病毒肺炎疫情分析及对策[J]. 实用预防医学, 2020, 27(4):393-395. [8] 胡世雄, 徐巧华, 罗垲炜, 等. 湖南省新型冠状病毒肺炎感染者流行病学特征分析[J]. 实用预防医学, 2020, 27(4):385-388. [9] 李燕明, 施红. 老年新型冠状病毒肺炎诊断和治疗专家共识[J]. 中国医师杂志, 2020, 22(2):161-165. [10] 邓灵波, 周雯, 曾巧铃, 等. 疑似及确诊新冠肺炎的临床及胸部CT影像特点[J]. 医学信息, 2020, 33(4):4-7. [11] 刘松, 谢红, 余成新, 等. 新型冠状病毒肺炎患者的临床特点及肺部CT变化模式[J]. 放射学实践, 2020, 35(4):421-427. [12] 高艳, 戎冬冬, 安彦虹, 等. 新型冠状病毒肺炎的X线及CT表现[J]. CT理论与应用研究, 2020,29(2):147-154. [13] 温萌, 李家斌, 柳燕. 冠状病毒的研究进展与挑战[J]. 安徽预防医学杂志, 2020, 26(2):83-88,156. [14] 周生余, 王春亭, 张伟, 等. 山东省新型冠状病毒肺炎患者537例临床特征与救治效果[J]. 山东大学学报(医学版), 2020, 58(3):44-51. [15] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798):270-273. [16] Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa[J]. Int J Oral Sci, 2020, 12(1):8. [17] 徐晓涵, 翟所迪, 杨丽. 新型冠状病毒肺炎治疗中抗病毒药物的合理使用[J]. 中国医院用药评价与分析, 2020, 20(2):129-133,139. [18] 黄麟杰, 陈富超, 李志浩, 等. 新冠肺炎患者的药物治疗方案安全性分析[J]. 中国药理学通报, 2020, 36(5):737-738. [19] 兰小和, 林举择, 闵存云, 等. 新型冠状病毒肺炎患者肝损伤的机制及中医防治探究[J]. 中西医结合肝病杂志, 2020, 30(2):147-149. [20] 李新刚, 徐艳利, 王琳,等. 糖皮质激素在新型冠状病毒肺炎重型患者治疗中的临床研究[J]. 首都医科大学学报, 2020,41(3):345-349. [21] Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2[J]. Int J Antimicrob Agents, 2020, 55(3):105923.
2020, Vol. 27 
